Beta 1 -Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation
Amir M. Nia, Evren Caglayan, Natig Gassanov et al. · 2010
Read Beta 1 -Adrenoceptor Polymorphism Predicts Flecainide Action in Patients with Atrial Fibrillation by Amir M. Nia, Evren Caglayan, Natig Gassanov et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011421.txt.
Description
Amir Nia and co-authors showed in 2010 that a gene variant can predict how well a heart rhythm drug works. Flecainide steadies the heart in atrial fibrillation, a common rhythm disorder, yet patients respond unevenly for reasons doctors could not see. The team tested whether variation in the gene for a heart adrenaline receptor explained the difference.
Patients carrying a particular form of the receptor gene responded to the drug differently from those without it. A simple genetic test could therefore help doctors choose who should get this drug and who should try another first. That is the promise of personalized prescribing: less trial and error with drugs that carry real side effects. The study is a step toward heart care in which the prescription is matched to the patient's genes from the start.
Catalog record
| CREATOR | Amir M. Nia, Evren Caglayan, Natig Gassanov et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011421